# ASOcura

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/asocura

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Total disclosed funding: $14M
- Latest round: Series A (Jul 1, 2024)
- Investors on record: 2

## About

Established in 2017 and based in Suzhou, China, ASOcura operates as a small nucleic acid drugs developer that provides antisense oligonucleotide drugs. In July 2023, it closed a pre-series A+ round of funding from Herui Venture Capital. The company cooperates with Penguin Home. Yimin Hua, the founder of the company, was the principal inventor of Nusinersen. In July 2024, the firm raised CNY 100 million in series A funding.

The company targets RNA splicing and RNA editing, and provides small nucleic acid drugs for patients with Duchenne muscular dystrophy (DMD) and spinocerebellar ataxia type 3 (SCA3). Products can alter the splicing signal sequence, orientation, and protein product of NA precursors.

The company’s revenue is generated by providing small nucleic acid drugs.

The company will use the series A funding to accelerate the advancement of products for indications such as Duchenne muscular dystrophy, spinocerebellar ataxia, and Huntington's disease and apply for registration of clinical trials.

## Funding rounds

- Series A, Jul 1, 2024, $14M — SDIC Venture Capital, Herui Venture Capital

## Investors

- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A
- Herui Venture Capital (https://capitalatlas.ai/funds/herui-venture-capital) — Series A